Literature DB >> 8586474

Detection of viability after myocardial infarction: available techniques and clinical relevance--a review.

J M Huitink1, F C Visser, J J Bax, C A Visser.   

Abstract

The differentiation of viable from nonviable myocardium in patients with myocardial infarction (MI) and left ventricular (LV) dysfunction is of important clinical relevance. It is now known that impaired LV function after infarction not always represents an irreversible process. LV ejection fraction is significantly reduced in many patients after infarction and, although abnormally contracting myocardial segments may result from irreversible scarring, numerous studies have shown that many asynergic zones have sustained metabolic activity. An accurate detection of myocardial viability aids in clinical decision making to select the appropriate therapy for patients with MI. Recently, cardiac imaging techniques that evaluate myocardial viability on the basis of myocardial perfusion, cell membrane integrity, metabolic activity and residual coronary reserve, have been developed with clinical success. These methods provide greater precision in the assessment of viable myocardium than can be achieved by analysis or coronary anatomy, regional function or the presence or absence of electrocardiographic Q waves, criteria that were used in the past. The clinical challenge is to predict which myocardial regions are viable and will improve systolic function after revascularization, thereby enhancing global LV function. In this review, the currently available imaging techniques for assessment of myocardial viability are discussed.

Entities:  

Mesh:

Year:  1995        PMID: 8586474     DOI: 10.1016/0167-5273(95)02430-5

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  1 in total

1.  QT dispersion and viable myocardium in patients with prior myocardial infarction and severe left ventricular dysfunction.

Authors:  Vuy Hun Li; Sharmila Dorbala; Dhiraj Narula; Gordon DePuey; Jonathan S Steinberg
Journal:  Ann Noninvasive Electrocardiol       Date:  2002-01       Impact factor: 1.468

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.